1. Home
  2. DMRC vs BDTX Comparison

DMRC vs BDTX Comparison

Compare DMRC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$7.23

Market Cap

174.3M

Sector

Technology

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.90

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
BDTX
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.3M
104.0M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
DMRC
BDTX
Price
$7.23
$1.90
Analyst Decision
Hold
Buy
Analyst Count
2
8
Target Price
★ $11.50
$10.00
AVG Volume (30 Days)
147.9K
★ 761.0K
Earning Date
11-06-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 130.71
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.99
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.07
$1.60
52 Week High
$17.47
$4.94

Technical Indicators

Market Signals
Indicator
DMRC
BDTX
Relative Strength Index (RSI) 61.53 48.71
Support Level $7.06 $1.79
Resistance Level $8.20 $1.93
Average True Range (ATR) 0.46 0.13
MACD 0.11 0.03
Stochastic Oscillator 61.17 50.93

Price Performance

Historical Comparison
DMRC
BDTX

About DMRC Digimarc Corporation

Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: